GlassScriptPhysician profile
Russell M Leboyer
NPI 1215101845
$2,008.85
in general payments reported to CMS, 2019-2025
24 companies · $161 in 2025
The $161 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $377 · 2020: $58.20 · 2021: $386 · 2022: $598 · 2023: $224 · 2024: $205 · 2025: $161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $590.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $590.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $391.67 | 2019-2025 | Precision 1, Clareon, Hydrus Microstent |
| Novartis Pharmaceuticals Corporation | $294.18 | 2019-2022 | |
| Allergan, INC. | $237.37 | 2019-2022 | |
| Abbvie INC. | $189.67 | 2022-2024 | |
| New World Medical,INC. | $135.21 | 2024-2025 | Clearpath, Ahmed Glaucoma Valve, Kahook Dual Blade |
| Oyster Point Pharma, INC. | $112.39 | 2022 | |
| Sun Pharmaceutical Industries INC. | $91.18 | 2019-2023 | Cequa |
| Biotissue Holdings INC. | $60.18 | 2019-2021 | |
| Carl Zeiss Meditec Ag | $58.20 | 2020 | |
| Horizon Therapeutics Plc | $44.57 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $42.96 | 2023-2024 | Miebo, Xiidra |
| Aerie Pharmaceuticals, INC. | $41.35 | 2021 | |
| Harrow Eye, LLC | $40.95 | 2025 | Vevye |
| Sight Sciences, INC. | $40.08 | 2021-2023 | Omni Surgical System |
| Thea Pharma INC. | $39.78 | 2023 | Iyuzeh |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec USA, INC. | $35.66 | 2025 | |
| Ani Pharmaceuticals, INC. | $27.06 | 2022 | |
| Coopervision INC. | $21.76 | 2021 | |
| Mallinckrodt Enterprises LLC | $20.95 | 2019 | |
| Shire North American Group INC | $18.66 | 2019 | |
| Dompe US, INC. | $17.68 | 2019 | |
| Tearlab Corp | $16.85 | 2019 | |
| Ocular Therapeutix, INC. | $15.90 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $14.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Russell Leboyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.